Belsky Marc 4
4 · Kezar Life Sciences, Inc. · Filed Jul 26, 2023
Insider Transaction Report
Form 4
Belsky Marc
Chief Financial Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−60,000→ 0 totalExercise: $22.85Exp: 2029-01-05→ Common Stock (60,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+60,000→ 60,000 totalExercise: $2.28Exp: 2029-01-05→ Common Stock (60,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+60,000→ 60,000 totalExercise: $2.28Exp: 2029-09-05→ Common Stock (60,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+220,000→ 220,000 totalExercise: $2.28Exp: 2031-01-07→ Common Stock (220,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−195,000→ 0 totalExercise: $6.84Exp: 2033-01-07→ Common Stock (195,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−60,000→ 0 totalExercise: $3.38Exp: 2029-09-05→ Common Stock (60,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−90,000→ 0 totalExercise: $3.29Exp: 2030-01-11→ Common Stock (90,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−220,000→ 0 totalExercise: $5.45Exp: 2031-01-07→ Common Stock (220,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+90,000→ 90,000 totalExercise: $2.28Exp: 2030-01-11→ Common Stock (90,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−140,000→ 0 totalExercise: $14.55Exp: 2032-01-04→ Common Stock (140,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+140,000→ 140,000 totalExercise: $2.28Exp: 2032-01-04→ Common Stock (140,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+195,000→ 195,000 totalExercise: $2.28Exp: 2033-01-07→ Common Stock (195,000 underlying)
Footnotes (6)
- [F1]Fully vested and exercisable.
- [F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
- [F3]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2020, subject to the Reporting Person continuing to provide service through each such date.
- [F4]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
- [F5]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
- [F6]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.